Key Takeaways NVO won FDA approval for oral Wegovy, the first GLP-1 obesity pill in the U.S.LLY has filed an NDA for its oral GLP-1 orforglipron.Lilly data show orforglipron helped patients maintain weight loss after switching from Wegovy or Zepbound.Earlier this week, the FDA approved Eli Lilly and Company’s (LLY) rival Novo Nordisk’s (NVO) oral version of the obesity drug Wegovy (semaglutide). Wegovy is the first oral GLP-1 drug to be approved in the United States, ushering in a new era of obesity treatme ...

Key Takeaways AMGN agreed to lower U.S. drug prices, align them with other developed markets and offer deep DTC discounts.AMGN expanded its AmgenNow program to Repatha, Aimovig and Amjevita with discounts of up to 80%.Amgen plans $2.5B in U.S. manufacturing and R&D investments tied to tariff exemptions.Amgen (AMGN) recently signed a landmark agreement with the Trump administration to lower drug prices in the United States.Through this deal, Amgen addresses the two major concerns that have plagued Big Pharma ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Sanofi has entered into a definitive agreement to acquire Dynavax Technologies for $15.50 per share, totaling approximately $2.2 billion, which has led to a 40% increase in Dynavax's shares in pre-market trading [1][4] Group 1: Acquisition Benefits - The acquisition enhances Sanofi's adult immunization portfolio by adding Dynavax's hepatitis B vaccine, Heplisav-B, which features a two-dose regimen over one month, compared to the traditional three-dose schedule over six months [2][4] - Heplisav-B's faster dosing schedule is expected to improve vaccination compliance among adults and healthcare systems [2] - The deal also includes Dynavax's shingles vaccine candidate, Z-1018, currently in phase I/II development, expanding Sanofi's pipeline in a growing market due to aging populations [3][4] Group 2: Market Opportunity - In the U.S., nearly 100 million adults born before 1991 are unvaccinated against hepatitis B, indicating a significant public health need and market opportunity for Sanofi [6] - Shingles affects approximately one in three adults, leading to complications that create sustained demand for effective adult vaccines, further enhancing commercial prospects for Sanofi [6] Group 3: Strategic Advantages for Dynavax - The acquisition positions Dynavax's vaccine portfolio within a global pharmaceutical leader, leveraging Sanofi's infrastructure and expertise to maximize commercial reach [7] - Sanofi's capabilities are expected to advance the shingles program and other pipeline assets more efficiently through later-stage development [7] - The transaction provides immediate cash value to Dynavax's shareholders and mitigates execution and funding risks [7] Group 4: Transaction Details - The deal is expected to close in the first quarter of 2026, subject to customary closing conditions, with Sanofi funding the transaction using available cash resources [8]

The Dow Jones Industrial Average was up 0.1% as of 9:45 a.m. Eastern. The S&P 500 index was up less than 0.1% and the Nasdaq Composite was down 0.1%. Markets will close at 1 p.m. ET for Christmas Eve and are closed for Christmas. Markets will reopen for a full day of trading on Friday, however volumes are expected to be light this week with the holiday and most investors having closed out their positions for the year. Much of the focus remains on the state of the U.S. economy and where the Federal Reserve w ...

Shares of Agios Pharmaceuticals surged nearly 15% in premarket trading on Wednesday after the US Food and Drug Administration approved an expanded use of its drug mitapivat, strengthening investor opt... ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

William Blair downgraded Dynavax (DVAX) to Market Perform from Outperform after Sanofi (SNY) announced it will acquire the company for $15.50 per share. The firm, which believes the acquisition "makes sense" given growing regulatory concerns around vaccines and investor questions on management's strategy for value creation, calls Sanofi a "logical acquisition partner." Alliance Global downgraded Spire Global (SPIR) to Neutral from Buy with a price target of $9, down from $17, until there is more evidence o ...

William Blair downgraded Dynavax (DVAX) to Market Perform from Outperform after Sanofi (SNY) announced it will acquire the company for $15.50 per share. The firm, which believes the acquisition "makes sense" given growing regulatory concerns around vaccines and investor questions on management's strategy for value creation, calls Sanofi a "logical acquisition partner." Alliance Global downgraded Spire Global (SPIR) to Neutral from Buy with a price target of $9, down from $17, until there is more evidence o ...

Core Viewpoint - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or similar derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses the author's personal opinions and does not reflect the views of Seeking Alpha as a whole [4].